Commodore Capital’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-3,711,286
Closed -$22.3M 39
2022
Q3
$22.3M Hold
3,711,286
3.58% 9
2022
Q2
$15.4M Hold
3,711,286
3.25% 12
2022
Q1
$14.1M Hold
3,711,286
3.15% 12
2021
Q4
$16.7M Buy
3,711,286
+592,525
+19% +$3.01M 3.87% 11
2021
Q3
$14.5M Buy
3,118,761
+22,032
+0.7% +$117K 3.83% 11
2021
Q2
$21.8M Buy
3,096,729
+665,024
+27% +$3.59M 7.61% 2
2021
Q1
$14.4M Buy
+2,431,705
New +$14.7M 5.72% 4

Other funds holding STSA

Commodore Capital's STSA Position: Q4 2022 in Review

Commodore Capital sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q4 2022, closing a stake of 3,711,286 shares — an estimated $22.3M sold.

Commodore Capital first reported a position in STSA in Q1 2021 and held it in 7 quarters. The position peaked at $22.3M in Q3 2022. 33 funds tracked by Wall St. Rank hold STSA as of Q4 2022.

  • Commodore Capital reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Commodore Capital sold 3,711,286 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $22.3M.
  • Commodore Capital first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 7 quarters.
  • Commodore Capital's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $22.3M in Q3 2022.
  • 33 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Commodore Capital's 13F filing for Q4 2022, filed 14 Feb 2023.